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Clinical trials present an ethical dilemma for pharmaceutical companies. While companies may want to undertake
and report these trials in an ethical manner, negative results can significantly affect product sales. There is
accumulating evidence that company-financed trials are biased in favor of the product that the company makes.
Ethical conduct in this article is defined as whether the trials are conducted in the best interests of the participants
and/or reported in the best interests of patients. Nine examples of how clinical trials are violating multiple articles in
the Declaration of Helsinki are discussed using concrete case reports from the literature. The recognition of ethical
problems in company run trials is not something new, but to date no meaningful action has been taken to resolve
this issue. What is necessary is to separate the financing of clinical trials from their conduct.
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Withholding dataBackground
Clinical trials form the basis for medical practice. Regu-
lators such as the Food and Drug Administration (FDA)
use them to decide whether or not to approve a new
drug. Doctors may not read the original research but
that research is incorporated into continuing medical
education talks, clinical guidelines and review articles.
Pharmaceutical companies fund the vast majority of
clinical trials [1] but these trials also present an eco-
nomic and ethical dilemma to companies. Trials using
rigorous methodology, the appropriate population
groups and that are properly analyzed and published in
a manner that accurately and completely presents their
conclusions are the ideal. At the same time, companies
need trials with positive results in order to get their
drugs on the market and drive sales. Negative trials can
have significant adverse effects on sales. Within one year
of the publication of the Women’s Health Initiative trial
that found that the estrogen/progestin combination
caused an increased risk of cardiovascular disease and
breast cancer in postmenopausal women, prescriptions
for Prempro, the most widely sold estrogen/progestinCorrespondence: jlexchin@yorku.ca
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reproduction in any medium, provided the orcombination, had declined by 66% in the United States
(US) [2].
Therefore, there is a strong temptation to deviate from
the ideal for economic reasons. The result is trials that
are unethical in some manner. Here the term ethical is
defined as whether the trials are conducted in the best
interests of the participants and/or reported in the best
interests of patients. The contention is not that every
industry-funded trial is unethical, but the accumulating
evidence provides strong grounds to believe that uneth-
ical behavior is not uncommon. A recent Cochrane re-
view examined the association between the source of
funding for trials and their results and conclusions. The
authors found that the odds ratio for positive outcomes
for drug studies sponsored by the manufacturing com-
pany was 2.15 (95% CI: 1.70 to 2.72) for results and 2.67
(95% CI 2.02 to 3.53) for conclusions [3]. Two separate
groups have looked at clinical trials submitted to the
FDA and then whether they were subsequently pub-
lished and how closely the results in the FDA submis-
sions matched those in the published versions. In both
cases, positive trials were much more likely to be pub-
lished and trials that had negative results when they
were reviewed by the FDA had positive results in journal
publications [4,5].This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ior at all stages of clinical trials from their design, to
whether or not ethical approval is obtained, the way that
the trials are conducted, the use of ghost writers to write
up the results, the withholding of data and finally the
use of Phase IV trials as marketing tools. Even more
importantly, is the violation of multiple articles about
the ethical conduct of clinical trials that are enunciated
in the Declaration of Helsinki [6].
Main text
Declaration of Helsinki – articles 17, 18 and 24: “Medical
research involving a disadvantaged or vulnerable popula-
tion or community is only justified if the research is
responsive to the health needs and priorities of this popu-
lation or community…”; “Every medical research study
involving human subjects must be preceded by careful
assessment of predictable risks and burdens to the individ-
uals and communities involved in the research …”;
“…After ensuring that the potential subject has understood
the information, the physician or another appropriately
qualified individual must then seek the potential subject’s
freely-given informed consent, preferably in writing. If the
consent cannot be expressed in writing, the non-written
consent must be formally documented and witnessed”.
Perhaps the most widely documented case of unethical
behavior is the trial that Pfizer conducted with its anti-
biotic trovafloxacin (Trovan) on children with meningitis
in Nigeria in 1996. As Stephens [7] points out, whereas
planning for the trial would have taken about a year or
longer in the United States, the trial in Nigeria was orga-
nized in just 6 weeks. Trovafloxacin not only had never
been used before in the treatment of meningitis but it was
being administered orally, a highly unusual way of treating
meningitis. Furthermore, there was already a proven ef-
fective treatment for meningitis in this type of resource
poor environment, intramuscular chloramphenicol that
was, in fact, being used by Médecins sans Frontières at a
nearby clinic to also treat children ill from the same men-
ingitis outbreak. It later also turned out that the letter
granting ethics approval was backdated and the local eth-
ics committee had been set up a year after the trial [7,8]. A
second, more recent example of the violation of article 17
comes from trials of olmesarten (Olmetec) between 2003–
2006. Olmesarten is a medication for the treatment of
hypertension, but these trials included children between
the ages of 1–16 years of age. While there might have
been a justification for treating children this young for
high blood pressure none was provided by the sponsor
(Daiichi Sankyo) [9].
Declaration of Helsinki – article 32: “The benefits,
risks, burdens and effectiveness of a new intervention
must be tested against those of the best current proven
intervention,”Both aripiprazole (Abilify) and quetiapine (Seroquel)
were tested against placebo in patients with schizophre-
nia despite the risks of a relapse while on placebo. What
is especially troubling about the quetiapine trials was
that they were only being conducted to test different for-
mulations of the same drug. While article 32 does con-
tain exceptions for the use of placebos these do not
apply in these cases [9].
Declaration of Helsinki – article 33: “At the conclusion
of the study, patients entered into the study are entitled
to be informed about the outcome of the study…”
Psaty and Rennie have documented a number of in-
stances where clinical trials have been stopped for com-
mercial, as opposed to medical, reasons. In discussing
the early termination of a trial comparing verapamil with
either a beta-blocker or a diuretic in the treatment of
hypertension, they note “the responsible conduct of
medical research involves a social duty and a moral re-
sponsibility that transcends quarterly business plans”
[10]. Clearly, if trials are stopped before completion,
then there will not be any outcomes related to safety or
efficacy to convey to patients.
Declaration of Helsinki – article 30: “Authors, editors
and publishers all have ethical obligations with regard to
the publication of the results of research. Authors have a
duty to make publicly available the results of their
research on human subjects and are accountable for the
completeness and accuracy of their reports. They should
adhere to accepted guidelines for ethical reporting…”
Article 30 does not explicitly mention the obligation of
companies to ensure that trials are fully and accurately
reported but since it is the companies that control the data
in the trials that they have funded, on face value article 30
should equally apply to them. There are a number of
instances where companies have been guilty of withhold-
ing data from investigators and from those conducting
systematic reviews. Full results of a trial looking at
whether adding HIV-1 Immunogen to the treatment of
AIDS patients would increase the efficacy of antiretrovirals
could not be published because the sponsor, Remune,
would not make the complete data set available to the
investigators [11]. Whether or not oseltamivir (Tamiflu)
lowers serious complications of influenza, such as
pneumonia, is still unknown more than 3 years after
Cochrane reviewers started trying to collect data for a
systematic review to answer the question. Despite initial
promises by Roche to provide full access to the data from
all of the clinical trials, the company ultimately refused to
do so citing a variety of reasons including confidentiality
and the fact that there was another ongoing systematic
review [12].
Besides the withholding of data, the practice of ghost
writing also violates article 30. Ghost writing is the prac-
tice whereby companies hire professional medical writers
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demic and subsequently appears without an acknow-
ledgement of the role of ghost writer. The obvious
concern is that the article is drafted by someone who
did not participate in the gathering or interpretation of
the data and the message in the article is one that has
been developed by the company to further its commer-
cial interests. Surveys have estimated the prevalence of
ghost writing is anywhere between 12% [13] and 75% in
industry-initiated trials [14]. One example of how ghost
writing distorts the medical literature is provided by
Amsterdam and McHenry in their account of the paroxe-
tine 352 study for the treatment for patients with bipolar
type I major depressive disorder [15]. “The paroxetine
352 study manuscript was ghostwritten by Scientific
Therapeutic Information, Inc. (STI) with funds provided
by GSK; however, neither STI, the ghostwriter, nor
GSK’s role in the production of the manuscript was
acknowledged in the published article.” Although the
primary outcome measure, whether paroxetine or im-
ipramine was superior to placebo, was negative, the
published article concluded that both drugs were effica-
cious in a post hoc subgroup.
Declaration of Helsinki – article 21: “Medical research
involving human subjects may only be conducted if the
importance of the objective outweighs the inherent risks
and burdens to the research subjects.”
Phase IV trials are those undertaken once the drug is
on the market. These trials are often undertaken not for
scientific reasons but in order to enhance sales, so-called
“seeding trials”. One anonymous former industry
employee, writing in the BMJ, talked about how some of
the studies he oversaw were designed to support a mar-
keting message, e.g., to show a questionable advantage
over a competitor or to increase the awareness of the
condition within the medical community, not to evaluate
the overall benefit:harm ratio of the drug [16]. The latest
example of this practice is the multiple studies under-
taken, mostly in developing countries, of the new insulin
analogues. These trials had limited scientific value but
enormous commercial value in promoting the wider use
of more expensive insulin products [17].
Discussion and conclusion
Documentation of these and other abuses is not some-
thing new. Bero and Rennie back in 1996 showed that
industry funding negatively affected the content and
quality of drug studies [18]. The persistence of unethical
practices for at least a decade after the Bero and Rennie
article appeared is one piece of evidence that in the time
period between the mid 1990s to the mid 2000s industry
practices did not change. A second, even more compel-
ling example that at least one company continued to
behave unethically, despite promising to reform, isPfizer’s actions in the mid 2000s. In January 2004 when
Pfizer pleaded guilty to marketing gabapentin (Neurontin)
for unapproved uses its lawyers assured the United States
Attorney’s Office that this practice would stop. However,
in 2009, Pfizer once again pleaded guilty to the same prac-
tice, this time regarding the marketing of valdecoxib
(Bextra) [19]. Whether industry has reformed now will
probably not become apparent for at least 5 years as
evidence of unethical practice is typically slow to manifest
and often relies on documents revealed through court
cases.
The existence of unethical practices is a serious prob-
lem not only because of the way that patients enrolled in
clinical trials are treated but because of their effects on
the quality of care that patients ultimately receive. The
solution is simple in concept but politically very
unappealing to those with the power to implement it – a
separation between the funding of clinical trials and their
conduct, analysis and write up. The Drug Utilization Acts
of 1975 and 1977 and the Drug Regulation Reforms Acts
of 1978 and 1979 proposed that the responsibility for clin-
ical testing be transferred to the federal government [20].
More recently, critics of the current system have advo-
cated that companies wishing to conduct clinical trials
continue to fund them but the money would go to an
independent institution such as the National Institutes of
Health that would organize and manage clinical trials and
the data that comes out of them [21,22]. For the sake
of patients the time has come to act on these
recommendations.
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